Krystal Biotech sells priority review voucher for $100M


It acquired the PRV acquired earlier this year after receiving accelerated approval in May of another product to treat a rare pediatric disease.

Previous UPMC Health Plan names new chief risk and compliance officer
Next Albuquerque's hottest ZIP codes for rising home prices